1 / 5

Inventorship and Ownership

Inventorship and Ownership. Patent Law 4.27.04. United States Patent 4,837,208 Rideout ,   et al. * June 6, 1989 Treatment of human viral infections Abstract

cherylhansen
Download Presentation

Inventorship and Ownership

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Inventorship and Ownership Patent Law 4.27.04

  2. United States Patent 4,837,208 Rideout ,   et al.* June 6, 1989 Treatment of human viral infections • Abstract • Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose. • Inventors: Rideout; Janet L. (Raleigh, NC); Barry; David W. (Chapel Hill, NC); Lehrman; Sandra N. (Durham, NC); St. Clair; Martha H. (Durham, NC); Furman; Phillip A. (Durham, NC) Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC) [*] Notice: The portion of the term of this patent subsequent to February 9, 2005 has been disclaimed.Appl. No.: 110377Filed: October 20, 1987

  3. AZT: AIDS Healthcare Found. v. GlaxoSmithKline Andrews Number 43.4.3.1AIDS Advocacy Group Seeks to Invalidate AZT PatentsAIDS Litigation ReporterVolume 16, Issue 3 [Published 11/4/2002]Saying that patents now held on AZT and other AIDS-related drugs by GlaxoSmithKline were obtained through fraudulent statements to the U.S. Patent Office and were based on publicly funded research, an AIDS advocacy group has amended its recent antitrust suit to include a request that the patents be invalidated so U.S. residents can take advantage of cheaper, generic versions of the drugs. AIDS Healthcare Foundation v. GlaxoSmithKline PLC et al., No. 02-5223 TJH, first amended complaint filed (C.D. Cal., W. Div., 10/15/2002)

  4. Lawsuit Challenges Patent on AZT AIDS TREATMENT NEWS No. 124 - April 5, 1991John S. James A lawsuit prepared by Public Citizen, a nonprofit public interest group founded by Ralph Nader, has challenged Burroughs Wellcome's 1988 patent on AZT (brand name Retrovir). The lawsuit claims that the patent is invalid because "the company did not conceive, develop or demonstrate the utility of the drug, nor did it name all of the inventors in its patent application," according to a March 19 press release from Public Citizen. "This lawsuit will establish the public's right to a fair price, and it gives the government a vehicle to challenge Burroughs Wellcome's monopoly." Plaintiffs include the PWA Health Group in New York, and two individuals in Washington, D. C., who are using AZT. Burroughs Wellcome's press release of the same date claimed that its scientists "were the first to conceive the use of the chemical AZT for the treatment of HIV infection in humans" -- the basis of the company's use patent, and that challenging the patent now, "more than five years after its filing...could have a chilling effect on innovation in the United States and could discourage future AIDS research." The press release also states that the company has supported "in whole or in part, more than 90 Retrovir-related clinical trials involving some 10,000 patients worldwide," and that the current price of approximately $2,200 per year for the dose of 500 mg per day "represents a 70 percent reduction in cost of therapy as a result of price decreases and reduced dosage since the drug was first marketed in 1987."

More Related